46.37
-0.20
(-0.43%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 46.06 - 46.67 |
| 52 week | 25.12 - 47.23 |
| Open | 46.42 |
| Vol / Avg. | 515,998.00/518,522.00 |
| Mkt cap | 2.65B |
| P/E | 33.23 |
| Div/yield | - |
| EPS | 1.40 |
| Shares | 57.08M |
| Beta | 1.33 |
| Inst. own | 102% |
Events
Aug 5, 2013
Q4 2013 PAREXEL International Earnings Release
Jun 26, 2013
PAREXEL International 2013 Investor Day
- 8:30AM EDT -
Jun 18, 2013
PAREXEL International at Wells Fargo Health Care Conference
- 10:35AM EDT -
Jun 12, 2013
PAREXEL International at Goldman Sachs Healthcare Conference
- 7:00PM EDT -
Jun 12, 2013
PAREXEL International at William Blair Growth Stock Conference
- 10:40AM EDT -
Jun 3, 2013
PAREXEL International at Jefferies Global Healthcare Conference
- 1:30PM EDT -
May 1, 2013
Q3 2013 PAREXEL International Earnings Conference Call -
Apr 30, 2013
Q3 2013 PAREXEL International Earnings Release
Mar 12, 2013
PAREXEL International at Barclays Healthcare Conference -
Mar 5, 2013
PAREXEL International at Raymond James Institutional Investors Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 5.64% | 3.90% |
| Operating margin | 6.99% | 5.40% |
| EBITD margin | - | 10.00% |
| Return on average assets | 6.98% | 4.26% |
| Return on average equity | 20.91% | 10.74% |
| Employees | 14,000 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. It operates it three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS) and Perceptive Informatics, Inc. (Perceptive). The Company�s product and service offerings include clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics / outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, post-marketing surveillance. In May 2013, PAREXEL International Corp acquired the entire share capital of HERON Group Ltd.
Officers and directors
| Josef H. von Rickenbach | Chairman of the Board, Chief Executive Officer | |
| Mark A. Goldberg M.D. | President, Chief Operating Officer | |
| James Francis Winschel Jr. | Chief Financial Officer, Senior Vice President | |
| Kurt A. Brykman | President - PACE and PAREXEL Consulting and Medical Communication Services | |
| Xavier Flinois | President - Perceptive Informatics | |
| Ulf Schneider Ph.D. | Chief Administrative Officer, Senior Vice President | |
| Douglas Alexander Batt | Senior Vice President, General Counsel, Secretary | |
| Anita Cooper Ph.D. | Senior Vice President, General Manager - Clinical Research Services | |
| Joseph C. Avellone M.D. | Senior Vice President - Clinical Research Services | |
| Gadi Saarony | Senior Vice President - Clinical Research Services |